If we know that MAC-associated cavitary lung disease is a marker of poor outcomes and/or refractory disease at the time of initial presentation, what is the rationale for waiting before deploying the amikacin liposome inhalation suspension?

If we know that MAC-associated cavitary lung disease is a marker of poor outcomes and/or refractory disease at the time of initial presentation, what is the rationale for waiting before deploying the amikacin liposome inhalation suspension?

If we know that MAC-associated cavitary lung disease is a marker of poor outcomes and/or refractory disease at the time of initial presentation, what is the rationale for waiting before deploying the amikacin liposome inhalation suspension?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Patrick Flume, MD

Patrick Flume, MD

Professor of Medicine and Pediatrics
Medical University of South Carolina
Powers-Huggins Endowed Chair for Cystic Fibrosis
University of South Carolina
Charleston, South Carolina